Brief: Ocumension Therapeutics Announces IND Approval For Multi-Regional Phase Iii Clinical Trial In U.S.
22/02/2021 15:05
Feb 22 (Reuters) - Ocumension Therapeutics 1477.HK :
* ANNOUNCES INVESTIGATIONAL NEW DRUG APPROVAL FOR INITIATING
A
MULTI-REGIONAL PHASE III CLINICAL TRIAL IN U.S. FOR OT-101
* OT-101 IS LOW-CONCENTRATION ATROPINE 0.01% EYE DROP TO
RETARD
PROGRESSION OF MYOPIA IN CHILDREN & ADOLESCENTS
Source text for Eikon: ID:nHKS9B955R
Further company coverage: 1477.HK
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application